Wednesday, October 8, 2025
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO North America > CEO Life > Food > Baxter to divest biopharma solutions unit for $4.25 billion

Baxter to divest biopharma solutions unit for $4.25 billion

in Food, Health, News
5 questions facing the pharma industry in 2023
Share on LinkedinShare on WhatsApp

Baxter International Inc said on Monday a private-equity group, which includes Warburg Pincus and Advent International, has agreed to buy its biopharma solutions unit for $4.25 billion.

Medical device makers such as Baxter have been grappling with supply-chain shortages that began during the pandemic, while rising costs of raw materials, labor and transportation added more pressure.

Baxter announced its intent to explore alternatives for its biopharma solutions business and spin off its kidney care units in January, stating the restructuring will allow greater alignment with the company’s manufacturing footprint.

Reuters was first to report the private-equity consortium was in the lead to acquire Baxter’s biopharma solutions business.

Baxter will receive after-tax proceeds of $3.4 billion, which it intends to use to pay down the debt the company incurred when it purchased medical device maker Hill-Rom Holdings for $10.5 billion in 2021. Baxter had a market value of $19 billion and total debt of $16.6 billion, as of December 31.

Baxter estimates the transaction will reduce the company’s earnings by about $0.10 per share in the fourth quarter.

The medical device maker’s biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as vaccines.

Through the deal, Advent International and Warburg Pincus will gain access to Baxter BioPharma solutions’ manufacturing facilities and about 1,700 employees in Bloomington, Indiana and Halle, Germany.

Private-equity firms have increasingly been investing in the drug development sector, which was deemed as risky, by coming up with deals that compensate them for the uncertainty involved.

Through the deal with Baxter, which is expected to close in the second half of 2023, the private-equity firms hope to strengthen their presence in the contract drug manufacturing space.

By Khushi Mandowara and Bhanvi Satija / Reuters

Tags: biomedical engineeringBiotechPharmacueticalUnited States

Related Posts

Beijing calls tariffs “blackmail”
News

China tipped to grow by 4.8% despite tariff pressures

AMD and OpenAI announce strategic partnership
News

AMD and OpenAI announce strategic partnership

Verizon’s Profit Falls 23% as Price Increases Slow Growth
News

Verizon names Dan Schulman as new CEO

French stocks tumble as PM resigns after 27 days
News

French stocks tumble as PM resigns after 27 days

WestJet and mechanics reach deal to end disruptive strike
News

Tesla video sparks speculation of new mass market vehicle

Job Openings Fell in May as Demand for Workers Remains Strong
News

Jobs Report delayed due to government shutdown

Bezos comments on AI industry ‘bubble’
News

Bezos comments on AI industry ‘bubble’

Goldman Sachs reports 22% jump in profits
News

Goldman Sachs CEO forecasts acceleration in the U.S. economy

Artificial sweeteners aged the brain by over 1.5 years, study says
Health

Artificial sweeteners aged the brain by over 1.5 years, study says

Elon Musk calls for resignation of FAA chief
News

Forbes reports Elon Musk as first person to hit $500 billion net worth

No Result
View All Result

Recent Posts

  • Nicole A. Kivisto, President and CEO of MDU Resources, sits down with CEO North America Magazine to share the company’s CORE strategy
  • AMD and OpenAI announce strategic partnership
  • China tipped to grow by 4.8% despite tariff pressures
  • Trilogy Metals shares explode 200% following Trump announcement
  • Business Ethics in Finance: Lessons From the Wells Fargo Scandal

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 212 432 5800

Avenida Chapultepec 480,
Floor 11
Mexico City
06700
MEXICO

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2025 JNews - Premium WordPress news & magazine theme by Jegtheme.